Clinical observations during the treatment period
n = 3/group . | Appetite loss . | Hematuria . | Edema . | Malaise, low activity . | Injection site reaction . | Elevated body temperature . |
---|---|---|---|---|---|---|
Vehicle | 0 | 0 | 0 | 0 | 0 | 0 |
CYP only | 1 | 0 | 1 | 0 | 0 | 0 |
CYP + GSK3277329 | 1 | 1 | 2 | 2 | 2 | 2* |
CYP + G-CSF | 0 | 0 | 0 | 3 | 0 | 0 |
n = 3/group . | Appetite loss . | Hematuria . | Edema . | Malaise, low activity . | Injection site reaction . | Elevated body temperature . |
---|---|---|---|---|---|---|
Vehicle | 0 | 0 | 0 | 0 | 0 | 0 |
CYP only | 1 | 0 | 1 | 0 | 0 | 0 |
CYP + GSK3277329 | 1 | 1 | 2 | 2 | 2 | 2* |
CYP + G-CSF | 0 | 0 | 0 | 3 | 0 | 0 |
Values reflect the number of animals in each group displaying a clinical observation. Appetite loss was defined as not consuming all food provided at daily feeding. Hematuria was noted if red discolored urine was seen. Edema was noted in animals with swollen eyelids or scrotum. Malaise was indicated if the animal did not show normal alert activity. Injection site reaction was noted if site was swollen and reddened for >24 hours. Elevated body temperatures were noted if animals presented with a temperature between 38°C and 40°C.
CYP, cyclophosphamide.
Noted on days 14 to 19 (see Figure 6).